Bristol Myers Squibb released a large batch of data today for the American Society of Hematology meeting. They have over 95 presentations covering their blood cancer portfolio. The main updates are on their pipeline assets. Iberdomide is showing sustained responses in newly diagnosed multiple myeloma, and golcadomide is delivering durable results in lymphoma. They also shared long-term data for Breyanzi that confirms survival benefits in large B-cell lymphoma. Management highlighted their targeted protein degradation platform as a key focus with these results.